NO953643L - Nytt middel til kontroll av celleaktivitet - Google Patents

Nytt middel til kontroll av celleaktivitet

Info

Publication number
NO953643L
NO953643L NO953643A NO953643A NO953643L NO 953643 L NO953643 L NO 953643L NO 953643 A NO953643 A NO 953643A NO 953643 A NO953643 A NO 953643A NO 953643 L NO953643 L NO 953643L
Authority
NO
Norway
Prior art keywords
domain
agent
cell
cell activity
endosome
Prior art date
Application number
NO953643A
Other languages
English (en)
Other versions
NO953643D0 (no
Inventor
John Robert North
Conrad Padraig Quinn
Keith Alan Foster
Clifford Charles Shone
Original Assignee
Speywood Lab Ltd
Microbiological Reasearch Auth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB1994/000558 external-priority patent/WO1994021300A1/en
Application filed by Speywood Lab Ltd, Microbiological Reasearch Auth filed Critical Speywood Lab Ltd
Publication of NO953643D0 publication Critical patent/NO953643D0/no
Publication of NO953643L publication Critical patent/NO953643L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Foreliggende oppfinnelse beskriver et nytt middel for målrettet kontroll av pattedyrcelleaktivitet. Spesielt blir middelet anvendt til å kontrollere inter- aksjonen av spesielle celletyper med deres ytre mil- jø. Middelet har anvendelse som et legemiddel for behandling av et utvalg av lidelser. Et middel som angitt i oppfinnelsen omfatter tre domener B, T og E bundet sammen på følgende måte: domene B - - domene T - - domene E, hvor domene B er bindingsdomenet som binder middelet til et bindingssete på cellen som gjennom- går endocytose for å produsere et endosom, domene T er translokasjonsdomenet som translokerer middelet (med eller uten bindingssete) fra innsiden av endosomet gjennom den endosomale membran inn i cytosol til cellen, domene E er effektor- domenet som inhiberer evnen til de resirkulerbare membranvesikler til å transportere de integrerende membranproteiner til cellens overflate.
NO953643A 1993-03-19 1995-09-15 Nytt middel til kontroll av celleaktivitet NO953643L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939305735A GB9305735D0 (en) 1993-03-19 1993-03-19 Novel agent for controlling cell activity
PCT/GB1994/000558 WO1994021300A1 (en) 1993-03-19 1994-03-18 Novel agent for controlling cell activity

Publications (2)

Publication Number Publication Date
NO953643D0 NO953643D0 (no) 1995-09-15
NO953643L true NO953643L (no) 1995-11-16

Family

ID=10732382

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953643A NO953643L (no) 1993-03-19 1995-09-15 Nytt middel til kontroll av celleaktivitet

Country Status (24)

Country Link
US (1) US20080070278A1 (no)
EP (1) EP0689459B1 (no)
JP (2) JP4300265B2 (no)
KR (1) KR960700756A (no)
CN (1) CN1195551C (no)
AT (1) ATE228856T1 (no)
AU (1) AU671203C (no)
BR (1) BR9406232A (no)
CA (1) CA2158647A1 (no)
CZ (1) CZ242695A3 (no)
DE (1) DE69431832T2 (no)
DK (1) DK0689459T3 (no)
ES (1) ES2183836T3 (no)
FI (1) FI954390A (no)
GB (1) GB9305735D0 (no)
HU (1) HU217220B (no)
IL (1) IL109045A0 (no)
IN (1) IN178499B (no)
NO (1) NO953643L (no)
NZ (1) NZ262484A (no)
PL (1) PL178895B1 (no)
PT (1) PT689459E (no)
SG (1) SG73411A1 (no)
SK (1) SK115595A3 (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305735D0 (en) * 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
ATE227739T1 (de) * 1998-05-13 2002-11-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
GB9926875D0 (en) * 1999-11-12 2000-01-12 Microbiological Research Agenc Use of lytic toxins and toxin conjugates
GB0321344D0 (en) * 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
DE602004025781D1 (de) * 2003-11-14 2010-04-15 Starhome Gmbh Steuerung von ankommenden Anrufen für Roamingteilnehmer eines zellularen Mobilfunknetzes
US8399400B2 (en) * 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
US7659092B2 (en) * 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
EP2310028B1 (en) * 2008-06-12 2016-11-16 Ipsen Bioinnovation Limited Fusion proteins for use in the treatment of acromegaly
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US10647750B2 (en) 2015-01-09 2020-05-12 Ipsen Bioinnovation Limited Cationic neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
JP7186228B2 (ja) 2018-02-26 2022-12-08 イプセン バイオファーム リミテッド 非細胞毒性プロテアーゼの注入を案内するための超音波の使用
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
EP4297773A1 (en) 2021-03-30 2024-01-03 Ipsen Biopharm Limited Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders
JP2024513191A (ja) 2021-03-30 2024-03-22 イプセン バイオファーム リミテッド 疼痛及び炎症性障害の処置
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
EP0329184A3 (en) * 1988-02-19 1990-05-23 Neorx Corporation Antimers and antimeric conjugation
US5045451A (en) * 1988-10-26 1991-09-03 Board Of Regents Methods for screening antibodies for use as immunotoxins
WO1990010692A1 (en) * 1989-03-15 1990-09-20 University Of Florida Monoclonal antibody for use in detection and treatment of childhood leukemia
US5300496A (en) * 1991-09-30 1994-04-05 The University Of British Columbia Complexed vanadium for the treatment of diabetes mellitus
US5877295A (en) * 1992-09-30 1999-03-02 The Center For Blood Research Antibodies which bind a subpopulation of Mac-1 (CD11b/CD18) molecules which mediate neutrophil adhesion to ICAM-1 and fibrinogen
GB9305735D0 (en) * 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity

Also Published As

Publication number Publication date
EP0689459A1 (en) 1996-01-03
WO1994021300A2 (en) 1994-09-29
SK115595A3 (en) 1997-02-05
JPH09500867A (ja) 1997-01-28
GB9305735D0 (en) 1993-05-05
FI954390A (fi) 1995-11-17
HU9502673D0 (en) 1995-11-28
AU6217594A (en) 1994-10-11
HUT76556A (en) 1997-09-29
US20080070278A1 (en) 2008-03-20
DK0689459T3 (da) 2003-03-24
ES2183836T3 (es) 2003-04-01
DE69431832D1 (de) 2003-01-16
BR9406232A (pt) 1996-01-09
CZ242695A3 (en) 1996-04-17
AU671203B2 (en) 1996-08-15
CN1195551C (zh) 2005-04-06
JP4740206B2 (ja) 2011-08-03
PL178895B1 (pl) 2000-06-30
FI954390A0 (fi) 1995-09-18
EP0689459B1 (en) 2002-12-04
DE69431832T2 (de) 2003-04-10
JP2007302696A (ja) 2007-11-22
SG73411A1 (en) 2000-06-20
CA2158647A1 (en) 1994-09-29
KR960700756A (ko) 1996-02-24
IN178499B (no) 1997-05-03
ATE228856T1 (de) 2002-12-15
NO953643D0 (no) 1995-09-15
IL109045A0 (en) 1994-06-24
JP4300265B2 (ja) 2009-07-22
PL310698A1 (en) 1995-12-27
AU671203C (en) 2003-02-27
NZ262484A (en) 1996-08-27
PT689459E (pt) 2003-04-30
HU217220B (hu) 1999-12-28
CN1124929A (zh) 1996-06-19

Similar Documents

Publication Publication Date Title
NO953643L (no) Nytt middel til kontroll av celleaktivitet
NO974845D0 (no) Clostridale foksinderivater som er i stand til å modifisere periferiske sanseafferente funksjoner
ATE476495T1 (de) Bazillus thuringiensis und dessen insektizide proteine
PT1200105E (pt) Factor viii modificado
NO20061455L (no) 2,6 dioksopiperidin samt farmasoytiske preparater som inneholder disse
ES2176177T3 (es) Procedimiento para aumentar la acumulacion de esteroles en s. cerevisiae por transformacion de un mutante.
ES2139740T3 (es) Cola de fibrina de dos componentes.
AU6839898A (en) Vaccine composition for preventing or treating c hepatitis
Tikhonov et al. Furin cleavage of the hiv‐1 tat protein
NO960710D0 (no) Nye tripeptider nyttige i immun- og CNS-terapi
BR9813102A (pt) Derivados de ácido metilenobisfosfÈnico novos

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application